EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Radiomics-Based Prediction of Bone Metastases from Baseline Prostate MRI in Prostate Cancer: A Systematic Review and Critical Appraisal

Nicholas A. Clausen, Hugo C. Temperley, Cormac B. Mulhall, Benjamin M. Mac Curtain, Louise C. McLoughlin, Michael E. Kelly, Ardeshir R. Rastinehad

BioTech · 08.11.2026 · 15 (5) · 102

DOI: 10.3390/biotech15050102 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BioTech, online erschienen am 08.11.2026. Verfasst von Nicholas A. Clausen und 6 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Whether bone metastasis is present at diagnosis determines curative versus systemic treatment of prostate cancer, yet referral for advanced staging relies on imperfect risk stratification; magnetic resonance imaging (MRI) radiomics has been proposed to predict metastatic status from routinely acquired staging imaging.

Methods

This systematic review (PROSPERO CRD420261463568) searched PubMed, Embase and Cochrane CENTRAL for studies of radiomic, deep-learning or hybrid models predicting bone-metastatic status from prostate MRI; incremental value over clinical predictors, reporting completeness, radiomics methodology and risk of bias were appraised.

Results

Six retrospective studies (1240 patients, 491 with bone metastasis, all from China; 322 contributed to the principal validation estimates) were included. Clinical-plus-radiomics models achieved validation areas under the receiver operating characteristic curve (AUCs) of 0.893–0.920 internally and 0.903 externally, with the highest estimate (0.928) from a multimodal model lacking clinical predictors. Only two studies compared clinical-only with combined models (AUC increments of 0.060 and 0.081).

Conclusions

Reported discrimination was generally high, but current evidence cannot establish that radiomics adds value beyond routine clinical predictors. These models are best understood as predictive biomarkers rather than detection tools; a potential triage role among patients below routine staging thresholds remains untested, and transportability beyond the high-prevalence cohorts studied is unproven; prospective multicentre validation is required before clinical use.

Zitieren

APA

Clausen, N. A., Temperley, H. C., Mulhall, C. B., Curtain, B. M. M., McLoughlin, L. C., Kelly, M. E., & Rastinehad, A. R. (2026). Radiomics-Based Prediction of Bone Metastases from Baseline Prostate MRI in Prostate Cancer: A Systematic Review and Critical Appraisal. BioTech, 15(5), 102. https://doi.org/10.3390/biotech15050102

Vancouver

Clausen NA, Temperley HC, Mulhall CB, Curtain BMM, McLoughlin LC, Kelly ME, et al. Radiomics-Based Prediction of Bone Metastases from Baseline Prostate MRI in Prostate Cancer: A Systematic Review and Critical Appraisal. BioTech. 2026;15(5):102. doi:10.3390/biotech15050102

BibTeX
@article{Clausen2026,
  author = {Clausen, Nicholas A. and Temperley, Hugo C. and Mulhall, Cormac B. and Curtain, Benjamin M. Mac and McLoughlin, Louise C. and Kelly, Michael E. and Rastinehad, Ardeshir R.},
  title = {Radiomics-Based Prediction of Bone Metastases from Baseline Prostate MRI in Prostate Cancer: A Systematic Review and Critical Appraisal},
  journal = {BioTech},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {102},
  doi = {10.3390/biotech15050102}
}
Kostenlos starten →